Compare BBSI & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | TBPH |
|---|---|---|
| Founded | 1965 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 711.6M | 824.9M |
| IPO Year | 1994 | 2013 |
| Metric | BBSI | TBPH |
|---|---|---|
| Price | $29.16 | $16.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $42.67 | $18.40 |
| AVG Volume (30 Days) | 233.8K | ★ 478.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | 5.05 | ★ 279.13 |
| EPS | ★ 2.08 | 2.06 |
| Revenue | ★ $920,432,000.00 | $15,386,000.00 |
| Revenue This Year | $6.59 | $1.04 |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | $13.99 | ★ $8.00 |
| Revenue Growth | ★ 9.50 | N/A |
| 52 Week Low | $25.33 | $8.33 |
| 52 Week High | $49.65 | $21.03 |
| Indicator | BBSI | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 62.14 |
| Support Level | $28.11 | $13.41 |
| Resistance Level | $29.49 | $19.04 |
| Average True Range (ATR) | 1.05 | 0.52 |
| MACD | 0.13 | 0.27 |
| Stochastic Oscillator | 60.37 | 98.23 |
Barrett Business Services Inc is a provider of payroll administrative services and staffing services. The company categories of services include professional employer services and staffing. Professional employer services offer payroll management, payroll tax services, and workers' compensation coverage solutions, as well as workforce management services, including hiring and termination of employees. Staffing offers temporary staffing services, as well as contract staffing, long-term or indefinite on-site management, and direct placement services. The company operates in the United States of America. It generates maximum revenue from the Professional employer service fees.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.